Zymedi
- Biotech or pharma, therapeutic R&D
A clinical stage Series A venture-backed biotech with strong legacy delivering first-in-class treatments in various diseases through our ARS (aminoacyl tRNA synthetases) platform, Pipeline includes a monoclonal antibody and small molecule targeting membrane bound and secreted KARS1 respectively with extensive preclinical evidence of activity in macrophage-driven pathologies including PAH, MASH, CKD and neuroinflammation. In addition, a C-VAX immune stimulant of TLR 2/6 for use as an adjuvant in cancer and infection. This broad ARS-focussed pipeline derives using Zymedi's proprietary Target Centric Platform (SUPREME™).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}